Fig. 6
PAR1-targeted chimeric antigen receptor (CAR)-T cells were located in MIA PaCa-2 tumors. Tumors were collected from mice bearing MIA PaCa-2 subcutaneous xenografts treated with PAR1CAR-T cells, mock-transduced T cells, non-transduced cluster of differentiation 3-positive (CD3+) T cells, or 1 × PBS. A Formalin-fixed paraffin-embedded tumor sections were cut and stained with hematoxylin and eosin for human Ki67, CD3, matrix metalloproteinase (MMP)-1, anti-PAR1, and CD44 expressions (black arrowheads). Images were captured using a microscope (BX50; Olympus) and camera (DP22) at × 400 or × 200 original magnification. Individual scale bars are shown. B The average H-score for each marker and comparisons between groups are shown in scatterplots (* p < 0.05, ** p < 0.01, and *** p < 0.001). C Serum samples from each treated mouse group during the treatment period were subjected to a cytokine analysis using the Human Cytokine/Chemokine Magnetic Bead Panel protocol from Milliplex. Data presented are the concentrations (con., pg/mL) of selected proinflammatory cytokines/cytokines (tumor necrosis factor (TNF)-α, interferon (IFN)-γ, interleukin (IL)-1α, IL-4, IL-6, IL-17A, and IL-15; upper and middle panels), a chemokine (growth-related oncogene (GRO); bottom panel), and growth factors (granulocyte–macrophage colony-stimulating factor (GM-CSF), platelet-derived growth factor (PDGF)-AA, and PDGF-AB/BB; bottom panels). Cytokines/chemokines with undetectable levels in serum samples were excluded (data not shown). Data are presented as the mean ± SD of three independent experiments